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Summary To investigate the role of ,B-tubulin isotype composition in resistance to paclitaxel, an anti-microtubule agent, human prostate
carcinoma (DU-145) cells were intermittently exposed to increasing concentrations of paclitaxel. Cells that were selected and maintained at
10 nm paclitaxel (Pac-10) were fivefold resistant to the drug. Pac-10 cells accumulated radiolabelled paclitaxel to the same extent as DU-145
cells and were negative for MDR-1. Analysis of Pac-10 and DU-145 cells by flow cytometry showed similar cell cycle patterns.
Immunofluorescent staining revealed an overall increase of a- and 1-tubulin levels in Pac-10 cells compared with DU-145 cells. Examination
of 3-tubulin isotype composition revealed a significant increase in pill isotype in the resistant cells, both by immunofluorescence and by
western blot analysis. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the isotypes confirmed the increase observed
for the ,,, by exhibiting ninefold higher ,,, mRNA levels and also showed fivefold increase of the Plv. transcript. In addition, analysis of
paclitaxel-resistant cells that were selected at increasing levels of the drug (Pac 2, 4, 6, 8 and 10) exhibited a positive correlation between
increasing P,,, levels and increasing resistance to paclitaxel. Increased expression of specific ,B-tubulin isotypes and subsequent incorporation
into microtubules may alter cellular microtubule dynamics, providing a defence against the anti-microtubule effects of paclitaxel and other
tubulin-binding drugs.
Paclitaxel has gained considerable attention in cancer therapy in
recent years and is successfully used in treating a variety of
tumours, including those ofthe breast, ovary and lung. In treatment
ofprostate cancer, paclitaxel is inactive when used as asingle agent
(Roth et al, 1993). However, in combination with estramustine,
another anti-microtubule agent, paclitaxel has significant activity
against hormone refractory prostate cancer (Hudes et al, 1995).
Despite its preclinical and clinical success, the exact mechanism
of action ofpaclitaxel is not known. At low concentrations, pacli-
taxel blocks mitosis by kinetic stabilization of spindle micro-
tubules (Jordan et al, 1993). Paclitaxel differs from the other
anti-microtubule agents such as vinblastine and colchicine by
causing microtubule polymerization instead of depolymerization.
The c4p-tubulin heterodimer is the major component of micro-
tubules. Most ofthe anti-microtubule agents, including paclitaxel,
vinblastine, colchicine and estramustine bind to 3-tubulin.
Paclitaxel binding sites on 3-tubulin were identified at the
N-terminal 31 amino acids and at residues 217-231 ofthe protein
(Horwitz et al, 1995). These two binding sites are part of the
colchicine binding site and are highly conserved among species.
Both a- and ,-tubulins are encoded by multigene families and
exist as several isotypes in cells. 3-Tubulin exists as six isotypes
that are evolutionarily conserved across species and differ from
each other predominantly at the carboxy terminus. Several in vitro
studies reported that tubulin isotype composition affects micro-
tubule assembly, drug sensitivity, drug binding and dynamics. For
example, 0311-depleted tubulin assembles into microtubules at a
faster rate than unfractionated tubulin (Banerjee et al, 1990).
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Pf31l-Tubulin also appears to be responsible for the slow-phase
binding of colchicine. Lu and Luduena (1993) have shown that
Pffi-depleted microtubules are more sensitive to paclitaxel-induced
polymerization than unfractionated tubulin. Previous studies from
our laboratory have shown overexpression ofm, and P,,1-tubulin
isotypes in human prostate carcinoma cells as a result ofresistance
to estramustine (Ranganathan et al, 1996). The clinical activity of
estramustine and paclitaxel combination therapy of prostate
cancer, despite the lack of activity of the single agents, prompted
us to investigate the effect of paclitaxel on ,-tubulin isotypes.
Thus, we have selected paclitaxel-resistant prostate carcinoma
cells and examined their 3-tubulin isotype composition. Our
results show that paclitaxel-resistant cells have altered
P-tubulin isotypes, similar to estramustine-resistant cells.
MATERIALS AND METHODS
Selection of non-MDR-1 mediated paclitaxel-resistant
cell line
Ourinitial attempts to selectpaclitaxel-resistant cells by continuous
exposure ofDU-145 cells to the drug resulted in complete cell kill,
even at concentrations as low as 2-3 nm. Thus, the following
strategy was used to select a paclitaxel-resistant cell line. To select
a non-MDR-l-mediated cell line, cells were exposed to paclitaxel
with and without 10gIM verapamil. DU-145 cells were treated with
paclitaxel (Calbiochem, LaJolla, CA, USA) for 24 h, once a week,
starting at 1 nM. After 2-3 weeks, the drug dose was escalated to
the next level at 1 nm increments. Pac 2, 4, 6 and 8 cell lines repre-
sent cells selected at 2, 4, 6 and 8 nM paclitaxel respectively.
Paclitaxel resistant (Pac-10) cells at 10 nm drug concentration were
maintained by acute 24-h exposure to the drug, once a week.
Cells were washed twice in phosphate-buffered saline (PBS) and
placed in drug-free medium after the drug exposure.
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Cytotoxicity assay
Cytotoxicity profiles of various anti-microtubule agents were
determined by the method of Skehan et al (1990). DU-145 and
Pac-10 cells were plated onto 96-well plates and exposed to
increasing concentrations of paclitaxel, estramustine (a gift from
Kabi Pharmacia, Lund, Sweden), vinblastine and colchicine
(Sigma Chemical St Louis, MO, USA) for 48 h. Cells were fixed,
stained with sulphorhodamine B, absorbances measured at 560 nm
and cell survivals were determined. Cytotoxicity assays were also
performed with doxorubicin (Sigma Chemical). The cytotoxicity
curves for Pac-10 cells with and without verapamil were similar
for paclitaxel. Pac-10 cells selected in the absence of verapamil
were negative for MDR-1, as shown below. Therefore, for all of
the experiments described below, Pac-10 cells selected in the
absence of verapamil were used. Cytotoxicity assays described
above were also performed by using Pac 2, 4, 6 and 8 cell lines to
determine the resistance to paclitaxel.
Drug accumulation and efflux assay
[3H]taxol was purchased from Movarek Biochemicals. DU-145
and Pac-1O were plated onto 24-well plates and grown to approxi-
mately 90% confluency. Cells were rinsed with PBS and incubated
in medium containing 0.1 jCi ml-1 [3H]taxol (spec. act. 11.6 Ci
mmol-') for 60 min at 37°C. At the end of incubation, cells were
washed thoroughly and intracellular 3H drug was determined by
scintillation counting of solubilized cells. This initial solubiliza-
tion was taken as zero point and used to determine the accumula-
tion ofthe drug. Samples were collected at 45 and 90 min after the
zero point to determine the efflux (Zilfou and Smith, 1995).
Flow cytometric cell cycle analysis
This was performed by standard methodology after propidium
iodide staining ofcellular DNA content. The percentage ofcells in
G, S and G2-M phases was calculated for DU-145 and Pac-10
cells (Vindelov et al, 1983).
3-Tubulin isotype staining by immunofluorescence
DU-145 cells and Pac-10 cells were plated on glass coverslips
and stained with P-tubulin antibodies, as described previously
(Ranganathan et al, 1996). PI,-, III- and Plv-antibodies were
purchased from Biogenex Laboratories (San Ramon, CA, USA).
General a-tubulin and ,-tubulin antibodies were purchased from
Sigma Chemical and used at 1:200 dilution. Texas-red conjugated
anti-mouse IgG (Molecular Probes, Eugene, OR, USA) was used
as a secondary antibody at 1:200 dilution. Stained cells were
scanned using the confocal microscopy system.
Protein analysis using western blots
Crude cytosolic lysates were prepared from DU-145 and Pac-10
cells, protein concentrations were estimated, run on 8% polyacryl-
amide gels and transferred onto PVDF membranes, as described
previously (Ranganathan et al, 1996). Blots were stained with
isotype-specific and non-specific 3-tubulin antibodies. Similar
analysis was performed using Pac 2, 4, 6 and 8 cell lines with
P.,I-antibodies.
RT-PCR analysis of P-tubulin isotype transcripts and
MDR-1
RNA was isolated from DU-145 and Pac-10 cell lines by a modi-
fied acid-guanidium lysis procedure (Chomczynski and Sacchi
1987). Primers were chosen using the Primer Detective Program
(Clontech, Palo Alto, CA, USA) and were synthesized by the
DNA core facility at Fox Chase Cancer Center. P-Tubulin isotype-
specific primers for the PI-, Pll-. 'In- and lv-isotypes were
described in detail previously (Ranganathan et al, 1996). The
MDR-1 primers (nucleotides 1325-1347, 1502-1523 ofthe cDNA
sequence) are specific for MDR-1 and span an intron to differen-
tiate between amplified products derived from RNA and DNA.
PCR products were analysed using agarose gel electrophoresis and
quantified by scanning densitometry.
RESULTS
Resistance to paclitaxel and response to other
anti-microtubule agents
As shown in Figure IA, Pac-10 cells were fivefold resistant to
paclitaxel (IC50 10nM) compared with the DU-145 cells (IC50
2 nM). Pac-10 cells were only twofold cross-resistant to estramus-
tine, with IC5 values of 2.5 gM for DU-145 cells and 5 gM for the
Pac- 10 cells. Similarly, twofold cross-resistance to colchicine was
seen with IC50 values of 50 and 100 nm for DU-145 and Pac-O0
cells respectively. The cytotoxicity curves for vinblastine were
similar for both cell lines with an IC50 value of 2 nm (data
not shown).
Paclitaxel resistance is not MDR-1 mediated
RT-PCRanalysis ofDU-145 cells andPac-lO cells showed thatboth
cell lines were negative for MDR-1 (Figure IB). In addition to this,
drug accumulation and efflux experiments using [3H]taxol have
shown that Pac-10 cells were very similar to DU-145 cells in taxol
accumulation. Efflux rates were also similar, with 50% of the drug
beingeliminated from cells by 90 min (Table 1). Thus, theresistance
of Pac-10 cells is not due to decreased paclitaxel entry or increased
efflux from the cells. Pac-10 cells were only twofold resistant to
doxorubicin compared with DU 145 cells, with IC50 values of 200
and 100 nmrespectively. This cross-resistance to doxorubicin, estra-
mustine and colchicine was probably due to the slower growth rate
of Pac-10 cells. Cell doubling times for DU 145 and Pac-10 cells
were approximately 18 h and 30 h respectively.
Cell cycle analysis
Paclitaxel is known to block cell cycle progression in late G2-M
phases. To examine its effects on Pac-10 cell cycle, DNA was
stained by propidium iodide and analysed by FACS. The results
showed that there were no alterations in the percentage of cells in
G1, S- or G2-M phases in paclitaxel-resistant cells compared with
the DU-145 cells (data not shown).
I-Tubulin isotype analysis by immunofluorescence and
western blots
When the DU-145 and Pac-lO cells were stained with isotype non-
specific tubulin antibodies and examined by confocal microscopy,
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incubated with [3H]taxol for 60 min at 370C. Cells were washed in PBS,
solubilized and accumulated [3H]taxol in cells and efflux of the drug from cells
was measured. Values represent means ±s.d. of three separate experiments
Time DU145 Pac-10
0 100% 100%
45 73.7 ± 6.5 67.6 ± 6.6
90 51.4 ± 4.9 45.1 ± 12.0
a
.C
co
0.1 1 10 100
Pacitaxel (nM)
Figure 1 (A) Cytotoxicity curves for paclitaxel. Drug-resistant cells and
parental DU-145 cells were treated with various concentrations of paclitaxel
for 48 h and cytotoxicities were determined as described in Materials and
methods. Data shown are means, bars = s.d. (B) MDR-1 analysis by
RT-PCR in DU-145 and paclitaxel resistant cells. RNA was isolated from both
cell lines and MDR-1 transcript was amplified by using MDR-1-specific
primers. RT-PCR products were analysed using agarose gel electrophoresis.
KB8-5, an MDR-1 expressing cell line, was used as a positive control
increased levels oftotal a- and 3-tubulin protein were observed in
the resistant cells (Figure 2). This was confirmed by western blot
analysis and the increase for total a- and ,-tubulin levels was
approximately threefold (data not shown). The 13- and PI-
isotypes were present at low levels in both cell lines. P11I-Isotype
levels increased significantly in Pac-10 cells when compared with
the parental DU-145 cells (Figure 2). This increase of PI,, was
confirmed by Western blot (see Figure 4) and quantitated to be
approximately fourfold elevated.
Analysis of P-tubulin isotypes by RT-PCR
Total RNA isolated from DU-145 and Pac-10 cells was used to
amplify the P-tubulin isotype transcripts and the PCR products
were analysed by agarose gel electrophoresis. The results were
quantitated by using 18S RNA for normalization as described
previously (Ranganathan et al, 1996) (Figure 3). These data show
that the 1I1-transcript levels were ninefold higher in Pac-10 cells
compared with DU-145 cells. In addition, there was a fivefold
increase of 1-isotype in the resistant cells. This increase of ,
isotype could notbe confirmedby western blot analysis because of
lack of I13-specific antibodies. ,B- and Blvb-transcripts were the
predominant isotypes in both cell lines and did not appear to
change in Pac-10 cells as a result of resistance. The ,B1-isotype
could not be detected in either of the cell lines under the PCR
conditions (26 cycles). At 30 cycles, a faint band was seen with
equal intensity in both cell lines (data not shown).
Correlation between paclitaxel resistance and ,1,,-levels
To investigate further the relationship between paclitaxel resis-
tance and the expression ofP.-isotype, cells that were selected at
different concentrations of the drug were analysed as shown in
Figure 4. Exposure to increasing levels of paclitaxel resulted in a
gradient ofincreasing resistance to the drug. Western blot analysis
of the cytosolic proteins from these cell lines showed a similar
gradient of increasing Pm11-isotype protein concentrations from
Pac-2 to Pac-10 cells (Figure 4, inset).
DISCUSSION
The PII,-isotype differs significantly from the other ,-tubulin
isotypes in its C-terminal amino acid composition (Sullivan,
1988). Therefore, it may differfrom the otherisotypes in its micro-
tubule assembly properties. Indeed, experiments performed with
bovine brain tubulin in the presence of microtubule associated
proteins (MAPs) have shown that the ,IB-depleted tubulin poly-
merizes at a faster rate than unfractionated tubulin (Banerjee et al,
1990). Further study from the same laboratory has shown that the
PIll-depleted tubulin was also more sensitive to paclitaxel-induced
polymerization compared with unfractionated tubulin (Lu and
Luduena, 1993). The critical concentration of tubulin required for
microtubule assembly in the presence of paclitaxel was approxi-
mately three times greater for the unfractionated bovine brain
tubulin compared with thepI,,-depleted tubulin. In addition micro-
tubules assembled from the I.B-depleted tubulin were shorter and
more resistant to podophyllotoxin and colchine compared with the
microtubules from unfractionated tubulin.
In earlier studies from our laboratory, we had observed increases
of the 13m- and [3.-tubulin isotypes in human prostate carcinoma
cells that had been made resistant to estramustine, a microtubule-
depolymerizing agent (Ranganathan et al, 1996). These cells were
also partially cross-resistant to paclitaxel. In this study, we observed
an increase inP.- and ,B-levels in paclitaxel resistant cells, similar
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Figure 2 Immunofluorescent staining of parental and drug-resistant cells with a- and 0-tubulin antibodies and ,-tubulin isotype-specific antibodies. Cells were
plated on coverslips, fixed and stained with the antibodies as descnbed in Materials and methods
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Figure 3 Quantification of the RT-PCR analyses of the j-tubulin isotype
transcripts for the drug-resistant and parental cell lines. Experiments were
conducted at least six times and the relative abundance oftranscripts was
calculated as a ratio of 18S to the isotype. DU145; *, PACIO
to the increases seen in estramustine-resistant cells. The positive
correlation between the extent of paclitaxel resistance and the
concentration ofI3.-isotype indicates that increased expression of
Bm-tubulin may play a significant role in resistance to thedrug.
Previous studies by other groups have shown that anti-micro-
tubule agents such as paclitaxel, vinblastine and colchicine act by
suppressing microtubule dynamics in vitro and in cells (Jordan et
al, 1992; Derry et al, 1995; Dhamodharan et al, 1995). Using puri-
fied 0-tubulin isotypes, Panda et al (1994) have shown that micro-
tubule dynamics are regulated by the tubulin isotype composition.
Microtubules assembled from purified aBIn-isotype were more
dynamic than microtubules made from a5xI- and a,rI3-isotypes or
unfractionated tubulin. Moreover, microtubules composed ofaP,B41-
and aIlv-isotypes were four times less sensitive to inhibition of
microtubule dynamics by paclitaxel (Derry et al, 1997). Based on
these studies, it is reasonable to speculate that the increases of
and P[ seen in our drug-resistant cell lines may alter the micro-
tubule dynamics in these cells to overcome the effects of anti-
microtubule agents. An additional explanation for the increases in
the isotypes may be altered drug-binding. This hypothesis is
supported by less efficient binding of ['4C]estramustine into
Figure 4 Correlation between paclitaxel resistance and P,,, tubulin levels.
Pac 2, 4, 6, 8 and 10 cell lines were treated with paclitaxel for 48 h and
compared with DU-145 cells to determine the level of resistance. Same cell
lines were also analysed for the ,,,, levels by western blot analysis as
described in the Materials and methods
0111-isotype, compared with other isotypes (Laing et al, 1997). The
drug-binding sites forpaclitaxel, however, appear to be in the areas
ofhigh homology among all ofthe isotypes.
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Haber et al (1995) have shown overexpression ofPI3-isotype in a
paclitaxel-resistant murine cell line that also overexpresses P-glyco-
protein. In contrast, the paclitaxel-resistant DU-145 cells described
in our study do not overexpress the MDR-1 gene product.
Alterations in ,B-tubulin isotypes due to paclitaxel resistance have
also been reported in other cell lines such as sarcoma, breast carci-
noma and ovarian carcinoma (Giannakakou et al, 1996; Mallarino et
al, 1996). These studies indicate that the drug-induced change in
isotype composition may be a general mechanism of resistance to
paclitaxel and other agents thatperturb microtubule dynamics.
Previously, we hypothesized that the favourable interaction of
paclitaxel and estramustine in the treatment ofpatients with hormone
refractory prostate cancer was based on the complementary but
different targets within the microtubule, i.e. pacitaxel binding to P-
tubulin and estramustine binding to microtubule-associated proteins
and tubulin (Dahllof et al, 1993; Speicher et al, 1994; Laing et al,
1997). The present results and ourprevious findings in estramustine-
resistant prostate cell lines suggest that resistance to paclitaxel and
estramustine may share acommonbasis despite thedifferingbinding
sites on the microtubule. Regardless of how an agent interacts with
the microtubule, the common effect of decreasing microtubule
dynamics may explain the similar alteration in 3-tubulin isotype
pattern in estramustine- and paclitaxel-resistant cell lines. Increasing
microtubule dynamics by altering tubulin isotypes may constitute a
general mechanism by which the cell can defend itself against the
large number of natural compounds which inhibit microtubule
dynamics. To further understand the significance ofthe [3m- andPr
isotypes in anti-microtubule drug therapy, transfection experiments
using theP and[lv cDNAs are underway.
As single agents, estramustine (Hudes, 1997) and paclitaxel
(Roth, 1993) are inactive in treatment of hormone refractory
prostate cancer but given together these drugs show significant
activity in preclinical (Speicher et al, 1992) and clinical studies
(Hudes et al, 1995). The mechanisms for greater than additive
preclinical and clinical anti-tumour activity ofpaclitaxel/estramus-
tine combination remains to be elucidated. Binding ofone ofthese
agents to the microtubules may alter the conformation of the
target, thus facilitating binding of the second agent. The C-
terminus of 3-tubulin peptide has been shown to be important in
MAP binding and folding of the molecule (Cross et al, 1994;
Fontalba et al, 1995). Differing significantly from the other
isotypes in its C terminus, the PI-isotope may also have distinct
MAP-binding properties. Thus, it may be important for the
synergistic activity ofthe paclitaxel/estramustine combination.
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